Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass.--()--Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced that an abstract highlighting preclinical data on its technology and therapeutic applications has been selected for presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL.

Details of the poster presentation on Tuesday, April 17, 2018, are as follows:

Poster Title: Enhancing Adoptive Cell Therapies Through Exogenous Regulation: Destabilizing Domains For Next-Generation CAR-T
Lead Author: Celeste Richardson, PhD
Session: Adoptive Cell Therapy - Poster Session 3
Abstract #: 3580 / 18
Date & Time: April 17, 2018, from 8:00am-12:00pm CT
Link to Abstract: http://www.abstractsonline.com/pp8/#!/4562/presentation/7518

About Destabilizing Domains

Obsidian uses Destabilizing Domains (DDs) to enable pharmacologic regulation of protein activity for next-generation cell and gene therapies. Obsidian’s DDs are small, fully-human protein domains that confer conditional stability to a fused payload protein. In the absence of a specific small molecule ligand the fusion protein is rapidly degraded, whereas in the presence of the ligand, the fusion protein becomes stable and functional. Obsidian uses this approach to equip engineered cells with controllable functions that can be precisely tuned by the administration of non-immunosuppressive, small molecule medicines that are readily available and dispensed by the treating physician.

About Obsidian Therapeutics

Obsidian Therapeutics is a biotechnology company developing next-generation cell and gene therapies with pharmacologic operating systems. Based upon founding work on destabilizing domains by Professor Thomas Wandless, a leading researcher in chemical and systems biology, Obsidian’s lead programs are CAR-T products that incorporate controllable functions for enhanced safety and efficacy. Obsidian was founded in 2015 by Atlas Venture and is funded by a strong syndicate of venture investors. The company is headquartered in Cambridge, Massachusetts. Please visit www.obsidiantx.com.

Contacts

The Yates Network
Kathryn Morris, 914-204-6412
kathryn@theyatesnetwork.com

Recent Stories

RSS feed for Obsidian Therapeutics, Inc.

Release Summary

An Obsidian Therapeutics abstract highlighting preclinical data on its technology and therapeutic applications has been selected for presentation at the 2018 AACR Annual Meeting.